Results 121 to 130 of about 75,344 (250)
Haematologica, 2010 Background Divalent metal transporter 1 (DMT1) is a widely expressed metal-iron transporter gene encoding four variant mRNA transcripts, differing for alternative promoter at 5′ (DMT1 1A and 1B) and alternative splicing at 3′ UTR, differing by a specific
Immacolata Andolfo +7 more
doaj +1 more source
Tendency of K562 chronic myeloid leukemia cells towards cell reprogramming
Turkish Journal of Hematology, 2018 Cancer cell reprogramming is a potential tool to study cancer progression, disease pathology, and drug sensitivity. Prior to performing cancer reprogramming studies, it is important to evaluate the stemness predisposition of cells that will be reprogrammed.
openaire +4 more sources
MicrobiologyOpen, Volume 15, Issue 2, April 2026.This study reveals that Porphyromonas gingivalis suppresses IFN‐γ signaling by downregulating STAT1 in macrophages. Gingipain protease activity and the Type IX Secretion System are essential for this immune evasion mechanism. These findings identify a novel bacterial strategy for host immune suppression and suggest new therapeutic targets for P ...
Shotaro Abe +4 more
wiley +1 more source
MedComm, Volume 7, Issue 4, April 2026.CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley +1 more source
Marine Drugs, 2008 Smenospongine, a sesquiterpene aminoquinone isolated from the marine sponge Dactylospongia elegans, was previously reported by us to induce erythroid differentiation and G1 phase arrest of K562 chronic myelogenous leukemia cells.
Motomasa Kobayashi +4 more
doaj
MedComm, Volume 7, Issue 4, April 2026.Targeted protein degradation represents a paradigm shift from traditional protein inhibition to complete protein elimination. This is achieved through three main strategies for degrading extracellular and membrane proteins: recruitment of cell‐surface LTRs, engagement of intracellular proteins, and receptor‐independent mechanisms.
Mengqing Zhao +6 more
wiley +1 more source
Journal of Associated Medical Sciences, 2018 Background: Leukemic stem cells (LSCs) play a central role in relapse and refractory cases of leukemia patients. This cell has been found to resist to a conventional chemotherapy more than leukemic cells.
Pawaret Panyajai +5 more
doaj
Loci specific epigenetic drug sensitivity. [PDF]
, 2020 Therapeutic targeting of epigenetic modulators offers a novel approach to the treatment of multiple diseases. The cellular consequences of chemical compounds that target epigenetic regulators (epi-drugs) are complex.
Pilko, Anna +2 more
core +1 more source
Manufacturing and clinical applications of non‐CAR‐T immune effector cells
Transfusion, EarlyView.
Thane Kubik +2 more
wiley +1 more source
Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases
MedComm, Volume 7, Issue 4, April 2026.Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang +3 more
wiley +1 more source